Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA First Amendment Plan: Series Of Guidances Rather Than Omnibus Rule

Executive Summary

FDA's policy on regulating commercial speech will be addressed through a series of guidances and rules related to specific areas of interest

You may also be interested in...

FDA Advertising Policy Adopts FTC’s “Reasonable Consumer” Standard

Silent on specifics of Internet promotion, an FDA draft guidance outlines broad criteria for the adequacy of risk information in promotional pieces.

FDA Approps Amendment Targets Chief Counsel Troy; Pfizer Ties Challenged

The House FDA appropriations bill cuts $500,000 from the budget of the chief counsel's office in response to actions taken by Chief Counsel Daniel Troy

IG Pharma Compliance Guide Has First Amendment Flaws, Attorney Says

The HHS Inspector General's pharmaceutical compliance guide may be the next battleground for First Amendment cases, Wiley, Rein & Fielding Attorney John Kamp said at an OIG compliance guide symposium in Princeton, N.J. July 23

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts